MondaySep 09, 2024 10:00 am

Frailty Trajectories Unaffected by Enrollment in Medicare Advantage

Medicare Advantage (MA) has become popular in recent years, with 2023 figures showing that the plans have more than 29 million enrollees. This figure represents 51% of all beneficiaries under Medicare. Plans under Medicare Advantage have lower premiums while covering additional benefits such as dental and vision. However, enrollees have access to a limited network of practitioners in comparison to enrollees of conventional Medicare. Additionally, beneficiaries of Medicare Advantage differ from beneficiaries of traditional Medicare across both socioeconomic and health status, with enrollees of the former plans being more likely to have lower incomes and be Hispanic or Black. Now,…

Continue Reading

FridaySep 06, 2024 10:00 am

Expert Says Alzheimer’s Disease Could Be an Autoimmune Illness

Alzheimer’s is a progressive illness that affects an individual’s behavior, thinking and memory. In the early stages, patients present with mild forgetfulness, and this progresses as time goes by, with patients at the late stage losing many physical abilities, among other things. This common form of dementia affects more than 50 million individuals around the globe. Often, individuals living with the illness are unable to recognize their spouses or even their own children when the illness is in its final stages. While the illness has no cure, this hasn’t deterred researchers from looking for one. Previous research had determined that…

Continue Reading

FridaySep 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets

With a focus on improving mitochondrial health, CNM-Au8® stands out among other therapies by targeting the nicotinamide adenine dinucleotide pathway to restore and protect neurological function. Nearly 2 million Americans are affected by amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”) or Parkinson’s disease. The global therapeutics markets for neurogenerative diseases are projected to grow substantially, driven by the growing prevalence of these conditions, rising geriatric population and the emergence of new therapies. Clene is preparing Phase 3 trials of CNM-Au8 in MS and ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function…

Continue Reading

WednesdaySep 04, 2024 10:00 am

New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer

Colorectal cancer presents in many forms, with the most common type being microsatellite-stable colorectal cancer. This cancer type is common in the initial stages of colon cancer and rectal cancer, occurring in roughly 85% of colorectal cancers. Unlike patients with microsatellite unstable colorectal cancer, patients with this cancer respond to few immunotherapies designed to activate their immune systems to fight the cancer. Now new research has determined a potential cause of other therapies failing and found a way to improve the treatment for patients with this indication. The study was led by Victoria Stary from MedUni Vienna’s Comprehensive Cancer Center.…

Continue Reading

WednesdaySep 04, 2024 9:45 am

Astiva Health Inc. Unveils New Community Outreach Initiative to Enhance Senior Wellness, Access to Care

The company is leveraging its extensive network of local partnerships to bring healthcare services directly into communities it serves Astiva is expanding network of activity centers, which are designed to be more than just places for medical care Astiva Health recognizes that true wellness goes beyond treating illness; it requires a proactive approach to health One of the pillars of Astiva Health’s approach to care is cultural responsiveness As the landscape of healthcare continues to shift toward more community-focused and personalized care, Astiva Health is launching a comprehensive community outreach initiative aimed at improving wellness and healthcare access for seniors across Southern…

Continue Reading

FridayAug 30, 2024 10:00 am

Yale Study Unravels Autism, Brain Growth Patterns

Autism spectrum disorder, commonly referred to as autism, is a neurodevelopmental disorder that affects how a person interacts with others, as well as how they learn, communicate and behave. This disorder’s symptoms usually appear in the first two years of an infant’s life and often present as repetitive behaviors and restricted interests. A new study led by researchers at Yale has found a pair of neurodevelopmental abnormalities that may be associated with autism, with their differences being influenced by brain size. The researchers determined that these abnormalities arose just weeks after the brain started developing. For their study, the researchers…

Continue Reading

ThursdayAug 29, 2024 10:30 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

INM-901 oral formulation shows encouraging results in preclinical studies High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will…

Continue Reading

WednesdayAug 28, 2024 10:00 am

Proposed US Law Would Direct Opioid Settlement Cash to Opioid Crisis Management

The opioid epidemic has seen millions lose their lives in the last 30 or so years. It began with prescription opioids and grew with heroin consumption, with the use of synthetic opioids such as fentanyl only making the situation worse. At the start of the year, Representatives Ashley Hinson and Marcy Kaptur introduced a measure that directs states to use settlement funds from pharmaceutical companies to address issues associated with opioids, such as prevention and treatment services. Allocating these funds to prevention and treatment services, including rehabilitation centers and opioid treatment programs, may help fight this crisis. These treatment programs…

Continue Reading

WednesdayAug 28, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily administered The company has submitted CNM-Au8 biomarker and efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a new drug application using the accelerated approval pathway for ALS CNM-Au8 has the potential to impact the ALS therapeutic market, as CNM-Au8 can help increase and improve survival rates and delay clinical worsening in ALS patients In MS, CNM-Au8 can work in conjunction with…

Continue Reading

TuesdayAug 27, 2024 10:00 am

AI Firms Gain Foothold in e-Commerce, Software, Healthcare Industries

Artificial intelligence (AI) seems to be making a mark on different industries, with some companies even recording growth in the healthcare and retail sectors. These companies are using artificial intelligence to address issues in these sectors, from rising medical bills to sizing issues in e-commerce. This indicates a possible shift in how industries are approaching different problems. One provider of AI-driven measurement solutions for e-commerce, MySize Inc., announced strong results from its second quarter. The company recorded a 53% increase in its revenues, driven primarily by its sizing tech and e-commerce platform powered by artificial intelligence. It also saw its…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050